Interventions for atypical haemolytic uraemic syndrome.

Pugh, Dan; O'Sullivan, Eoin D; Duthie, Fiona Ai; Masson, Philip; Kavanagh, David

Pugh, Dan; O'Sullivan, Eoin D; Duthie, Fiona Ai; Masson, Philip; Kavanagh, David.

Affiliation

Pugh D; Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
O'Sullivan ED; Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Duthie FA; Centre for Inflammation Research, Royal Infirmary of Edinburgh, Edinburgh, UK.
Masson P; Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Kavanagh D; Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.

Cochrane Database Syst Rev ; 3: CD012862, 2021 Mar 23.

Article in En | MEDLINE | ID: mdl-33783815

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Atypical Hemolytic Uremic Syndrome/drug therapy; Complement Inactivating Agents/therapeutic use; Antibodies, Monoclonal, Humanized/adverse effects; Atypical Hemolytic Uremic Syndrome/mortality; Bias; Complement Inactivating Agents/adverse effects; Glomerular Filtration Rate; Humans; Non-Randomized Controlled Trials as Topic; Quality of Life; Thrombotic Microangiopathies/drug therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement Inactivating Agents / Antibodies, Monoclonal, Humanized / Atypical Hemolytic Uremic Syndrome Type of study: Clinical_trials / Prognostic_studies / Qualitative_research / Systematic_reviews Limits: Humans Language: En Journal: Cochrane Database Syst Rev Journal subject: PESQUISA EM SERVICOS DE SAUDE Year: 2021 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google